Results 61 to 70 of about 6,491 (191)

Predictive Value of Modified Lung Ultrasound Score for Late Respiratory Diseases in Premature Infants: A Retrospective Cohort Analysis

Journal of Clinical Ultrasound, Volume 54, Issue 4, Page 915-923, May 2026.
This study is to assess the predictive value of the modified lung ultrasound score (mLUS) for late respiratory diseases in premature infants born before 32 weeks of gestation. It is recommended that the use of mLUS scoring be promoted in clinical practice for the early screening of high‐risk preterm infants.
Shuang Zheng, Yang Zhang, Yanan Gao, Huifen Chen, Sudan Liu   +4 more
wiley   +1 more source

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Valoración económica del palivizumab en prematuros en la Seguridad Social en Costa Rica [PDF]

, 2020
RESUMEN Introducción: El virus sincitial respiratorio afecta la salud de prematuros y el palivizumab puede reducir sus complicaciones. En Costa Rica se desconoce la eficiencia del uso de esta tecnología sanitaria.
Collazo Herrera, Manuel, Jiménez Herrera, Luis Guillermo, Gálvez González, Ana María   +2 more
core  

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey

The Turkish Journal of Pediatrics, 2012
The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel, Banu Mutlu, Sumru Kavurt, Ahmet Yağmur Baş, Nihal Demirel, Mesut Akyol, Omer Erdeve, Uğur Dilmen   +7 more
doaj  

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

, 2014
Marie Linder,1 Camilla Byström,1 Helle Kieler,1 Gunnar Bergman,2 Ann Haerskjold3,4 1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; 2Stockholm-Uppsala Department of Pediatric Cardiology ...
Linder M, Kieler H, Bergman G, Byström C, Haerskjold A   +4 more
core  

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]

Саратовский научно-медицинский журнал, 2016
Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М., Gavrilova E.S., Borisova А.А., Pazgalyova N.V., Panina O.S., Chernenkov Yu.V.   +5 more
doaj  

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

BMC Research Notes, 2012
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V, Baibarina Elena N, Degtiareva Elena A, Keshishyan Elena S, Lobzin Yurii V, Namazova-Вaranova Leyla S, Prodeus Andrey P, Gudkov Konstantin M, Kruglova Anna I, Schulz Gregory A, Notario Gerard F   +10 more
doaj   +1 more source

Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy

BMC Pediatrics, 2009
Background Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of
Mucchino Eleonora, Benincori Nicoletta, Mantovani Jessica, Pezzotti Patrizio, Di Lallo Domenico   +4 more
doaj   +1 more source

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria (Versão em Português), 2017
Objective: This study aims to describe real world palivizumab use and effectiveness in high‐risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source